Here's What Analysts Are Saying About Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best immunotherapy stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on February 10, setting a price target of $745.00.

The same day, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) highlighted its expanding immunology portfolio and pipeline, announcing that 36 abstracts across its immunology and inflammation portfolio and pipeline would be presented at the 2026 American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting set to be held February 27 to March 2 in Philadelphia, Pennsylvania.

Management reported that highlights include the first presentations from the novel Phase 3 allergen-specific programs exhibiting the potential of a first-in-class approach to addressing burdensome ocular symptoms in adults with cat and birch allergies. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) further stated that New Dupixent® analyses across dermatological, respiratory, and gastrointestinal diseases would also be presented, in collaboration with Sanofi.

In another development, Guggenheim lifted the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $975 from $865 on February 9, maintaining a bullish outlook with a Buy rating. The firm updated its model on the company after its earnings, and told investors that it sees key upcoming catalysts for the company, including the fianlimab/Libtayo LAG-3 data in melanoma, an FDA decision for the Eylea HD pre-filled syringe in Q2, and an NDA submission for cemdisiran in generalized myasthenia gravis in Q1.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a pharmaceutical company that develops, discovers, and commercializes therapies for several diseases, including cancer, eye disorders, and allergic conditions.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.